In the analysis of methylation in the IL2RA regulatory region, we selected CpG-sites based on results from two previous studies of the IL2RA gene in relation to disease status for either MS or type 1 diabetes (T1D) (13, 36). The gene discussed is IL2RA; the disease is myeloid sarcoma.